The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

Outbreaks of vaccine-preventable diseases such as measles, meningitis, and yellow fever are on the rise globally amid ...

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

More than 35,000 cases of the mosquito-borne disease have been reported on the French Indian Ocean island since August 2024.

The highest risk of transmission of SARS-CoV-2 was in the first 72 hours at room temperature and first 24 hours at 37℃.

The Advisory Committee on Immunization Practices (ACIP) has voted to expand the recommended use of GSK’s AREXVY (Respiratory ...

BANGKOK - Docquity, Southeast Asia’s largest community of healthcare professionals (HCPs), and global biopharmaceutical leader AstraZeneca developed ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

OAZisCare, digitally powered by DocquityCare, has advanced patient education and adherence for cancer care and RSV vaccines since 2024 The collaboration helps tackle Southeast Asia's healthcare needs, ...

A panel of federal health experts recommended expanded vaccine options for several diseases, including RSV, meningitis, and chikungunya.